Who Paid My Doc Search
Menu
Organisation paid for research Program year 2025 Source: CMS Open Payments

Montefiore Medical Center

Neither a doctor nor a teaching hospital

Research payments

$6,783,057

868 payments

Through program year 2025, Montefiore Medical Center is reported as receiving $6,783,057 in research payments, across 868 payments.

By program year

7 rows
Year Kind Amount Payments
2025 Research $428,702 115
2024 Research $820,153 169
2023 Research $897,704 159
2022 Research $1,025,081 93
2021 Research $1,697,997 151
2020 Research $1,353,309 111
2019 Research $560,111 70

Breakdown

Who paid Research payments · program years 2019–2025
  1. Novartis Pharmaceuticals Corporation $1,893,648 56 payments
  2. Pfizer Inc. $1,761,953 131 payments
  3. Merck Sharp & Dohme Corporation $508,344 22 payments
  4. Amgen Inc. $494,598 51 payments
  5. Insmed, Inc. $376,395 141 payments
  6. AbbVie, Inc. $309,568 85 payments
  7. Janssen Research & Development, LLC $200,873 4 payments
  8. Jazz Pharmaceuticals Inc. $189,052 1 payment
  9. Biohaven Pharmaceutical Holding Company Ltd. $114,940 75 payments
  10. Incyte Corporation $105,375 25 payments
Studies the money was for Research payments · program years 2019–2025
  1. A Prospective Phase II, Open-Label, Single-Arm, Multicenter, Study to Assess Efficacy and Safety of Seg101 (Crizanlizumab), in Sickle Cell Disease Patients With Priapism $649,997 4 payments
  2. A Phase 1 Open Label Crossover Study to Establish Bioequivalence Between the Proposed Soft Gel Talazoparib Capsule Formulation and the Current Talazoparib Commercial Formulation and to Estimate the Food Effect on Pharmacokinetics of the Proposed Talazoparib Soft Gel Capsule Formulation in Participants With Advanced Solid Tumors $568,599 9 payments
  3. A Phase 3 Randomized Doubleblind Placebocontrolled Study of Talazoparib With Enzalutamide in Metastatic Castrationresistant Prostate Cancer $496,816 15 payments
  4. Clinical Trial to Assess the Efficacy and Safety of An Alternative Dosing Regimen of Ribociclib in Breast Cancer $270,366 3 payments
  5. A Phase 3 Randomized Doubleblind Placebocontrolled Study of Talazoparib in Combination With Physicians Choice of Enzalutamide Or Abiraterone Acetateprednisone in Metastatic Castrationresistant Prostate Cancer With Dna Damage Repair Deficiencies $257,839 6 payments
  6. A Phase 3, Randomized, Double-Blind Study of Pembrolizumab versus Placebo in Combination With Adjuvant Chemotherapy With or Without Radiotherapy for the Treatment of Newly Diagnosed High-Risk Endometrial Cancer After Surgery With Curative Intent KEYNOTE-B21 , ENGOT-en11 , GOG-3053 $238,624 9 payments
  7. A Phase 3 Randomized, Double-blind Study of Ianalumab (VAY736) Versus Placebo in Addition to Eltrombopag in Patients With Primary Immune Thrombocytopenia (ITP) Who Had an Insufficient Response or Relapsed After First Line Steroid Treatment (VAYHIT2) $237,004 2 payments
  8. A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact $223,439 94 payments
  9. A Multicenter, Single-Arm, Open Label Trial to Evaluate Efficacy and Safety of Oral, Twice Daily Lnp023 in Adult Ahus Patients Who Are Naive to Complement Inhibitor Therapy $212,414 3 payments
  10. Prospective Comparison of Arni With Arb Given Following Stabilization in Decompensated Hfpef (Paraglide-Hfpef) $189,407 6 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record